A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2

Celine M Vachon, Daniel J Schaid, James N. Ingle, D. Lawrence Wickerham, Michiaki Kubo, Taisei Mushiroda, Matthew Philip Goetz, Erin E. Carlson, Soonmyung Paik, Norman Wolmark, Yusuke Nakamura, Liewei M Wang, Richard M Weinshilboum, Fergus J Couch

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Recent genetic studies have identified common variation in susceptibility loci that stratify lifetime risks of breast cancer and may inform prevention and screening strategies. However, whether these loci have similar implications for women treated with tamoxifen or raloxifene (SERMs) is unknown. We conducted a matched case–control study of 592 cases who developed breast cancer and 1,171 unaffected women from 32,859 participants on SERM therapy enrolled on NSABP P-1 and P-2 breast cancer prevention trials. We formed a quantitative polygenic risk score (PRS) using genotypes of 75 breast cancer-associated single nucleotide polymorphisms and examined the PRS as a risk factor for breast cancer among women treated with SERMs. The PRS ranged from 3.98 to 7.74, with a one-unit change associated with a 42 % increase in breast cancer (OR = 1.42; P = 0.0002). The PRS had a stronger association with breast cancer among high-risk women with no first-degree family history (OR = 1.62) compared to those with a positive family history (OR = 1.32) (Pintx = 0.04). There was also suggestion that PRS was a stronger risk factor for ER-positive (OR = 1.59, P = 0.0002) than ER-negative (OR = 1.05, P = 0.84) breast cancer (Pintx = 0.10). Associations did not differ by tamoxifen or raloxifene treatment, age at trial entry, 5-year predicted Gail model risk or other clinical variables. The PRS is a strong risk factor for ER-positive breast cancer in moderate to high-risk individuals treated with either tamoxifen or raloxifene for cancer prevention. These data suggest that common genetic variation informs risk of breast cancer in women receiving SERMs.

Original languageEnglish (US)
Pages (from-to)517-523
Number of pages7
JournalBreast Cancer Research and Treatment
Volume149
Issue number2
DOIs
StatePublished - 2015

Fingerprint

Tamoxifen
Breast Neoplasms
Selective Estrogen Receptor Modulators
Raloxifene Hydrochloride
Single Nucleotide Polymorphism
Genotype

Keywords

  • Mammographic density
  • Polygenic risk score
  • SERMs
  • Single nucleotide polymorphisms (SNPs)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. / Vachon, Celine M; Schaid, Daniel J; Ingle, James N.; Wickerham, D. Lawrence; Kubo, Michiaki; Mushiroda, Taisei; Goetz, Matthew Philip; Carlson, Erin E.; Paik, Soonmyung; Wolmark, Norman; Nakamura, Yusuke; Wang, Liewei M; Weinshilboum, Richard M; Couch, Fergus J.

In: Breast Cancer Research and Treatment, Vol. 149, No. 2, 2015, p. 517-523.

Research output: Contribution to journalArticle

Vachon, Celine M ; Schaid, Daniel J ; Ingle, James N. ; Wickerham, D. Lawrence ; Kubo, Michiaki ; Mushiroda, Taisei ; Goetz, Matthew Philip ; Carlson, Erin E. ; Paik, Soonmyung ; Wolmark, Norman ; Nakamura, Yusuke ; Wang, Liewei M ; Weinshilboum, Richard M ; Couch, Fergus J. / A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. In: Breast Cancer Research and Treatment. 2015 ; Vol. 149, No. 2. pp. 517-523.
@article{f8cb37095aeb45098634d6df481bb291,
title = "A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2",
abstract = "Recent genetic studies have identified common variation in susceptibility loci that stratify lifetime risks of breast cancer and may inform prevention and screening strategies. However, whether these loci have similar implications for women treated with tamoxifen or raloxifene (SERMs) is unknown. We conducted a matched case–control study of 592 cases who developed breast cancer and 1,171 unaffected women from 32,859 participants on SERM therapy enrolled on NSABP P-1 and P-2 breast cancer prevention trials. We formed a quantitative polygenic risk score (PRS) using genotypes of 75 breast cancer-associated single nucleotide polymorphisms and examined the PRS as a risk factor for breast cancer among women treated with SERMs. The PRS ranged from 3.98 to 7.74, with a one-unit change associated with a 42 {\%} increase in breast cancer (OR = 1.42; P = 0.0002). The PRS had a stronger association with breast cancer among high-risk women with no first-degree family history (OR = 1.62) compared to those with a positive family history (OR = 1.32) (Pintx = 0.04). There was also suggestion that PRS was a stronger risk factor for ER-positive (OR = 1.59, P = 0.0002) than ER-negative (OR = 1.05, P = 0.84) breast cancer (Pintx = 0.10). Associations did not differ by tamoxifen or raloxifene treatment, age at trial entry, 5-year predicted Gail model risk or other clinical variables. The PRS is a strong risk factor for ER-positive breast cancer in moderate to high-risk individuals treated with either tamoxifen or raloxifene for cancer prevention. These data suggest that common genetic variation informs risk of breast cancer in women receiving SERMs.",
keywords = "Mammographic density, Polygenic risk score, SERMs, Single nucleotide polymorphisms (SNPs)",
author = "Vachon, {Celine M} and Schaid, {Daniel J} and Ingle, {James N.} and Wickerham, {D. Lawrence} and Michiaki Kubo and Taisei Mushiroda and Goetz, {Matthew Philip} and Carlson, {Erin E.} and Soonmyung Paik and Norman Wolmark and Yusuke Nakamura and Wang, {Liewei M} and Weinshilboum, {Richard M} and Couch, {Fergus J}",
year = "2015",
doi = "10.1007/s10549-014-3175-4",
language = "English (US)",
volume = "149",
pages = "517--523",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2

AU - Vachon, Celine M

AU - Schaid, Daniel J

AU - Ingle, James N.

AU - Wickerham, D. Lawrence

AU - Kubo, Michiaki

AU - Mushiroda, Taisei

AU - Goetz, Matthew Philip

AU - Carlson, Erin E.

AU - Paik, Soonmyung

AU - Wolmark, Norman

AU - Nakamura, Yusuke

AU - Wang, Liewei M

AU - Weinshilboum, Richard M

AU - Couch, Fergus J

PY - 2015

Y1 - 2015

N2 - Recent genetic studies have identified common variation in susceptibility loci that stratify lifetime risks of breast cancer and may inform prevention and screening strategies. However, whether these loci have similar implications for women treated with tamoxifen or raloxifene (SERMs) is unknown. We conducted a matched case–control study of 592 cases who developed breast cancer and 1,171 unaffected women from 32,859 participants on SERM therapy enrolled on NSABP P-1 and P-2 breast cancer prevention trials. We formed a quantitative polygenic risk score (PRS) using genotypes of 75 breast cancer-associated single nucleotide polymorphisms and examined the PRS as a risk factor for breast cancer among women treated with SERMs. The PRS ranged from 3.98 to 7.74, with a one-unit change associated with a 42 % increase in breast cancer (OR = 1.42; P = 0.0002). The PRS had a stronger association with breast cancer among high-risk women with no first-degree family history (OR = 1.62) compared to those with a positive family history (OR = 1.32) (Pintx = 0.04). There was also suggestion that PRS was a stronger risk factor for ER-positive (OR = 1.59, P = 0.0002) than ER-negative (OR = 1.05, P = 0.84) breast cancer (Pintx = 0.10). Associations did not differ by tamoxifen or raloxifene treatment, age at trial entry, 5-year predicted Gail model risk or other clinical variables. The PRS is a strong risk factor for ER-positive breast cancer in moderate to high-risk individuals treated with either tamoxifen or raloxifene for cancer prevention. These data suggest that common genetic variation informs risk of breast cancer in women receiving SERMs.

AB - Recent genetic studies have identified common variation in susceptibility loci that stratify lifetime risks of breast cancer and may inform prevention and screening strategies. However, whether these loci have similar implications for women treated with tamoxifen or raloxifene (SERMs) is unknown. We conducted a matched case–control study of 592 cases who developed breast cancer and 1,171 unaffected women from 32,859 participants on SERM therapy enrolled on NSABP P-1 and P-2 breast cancer prevention trials. We formed a quantitative polygenic risk score (PRS) using genotypes of 75 breast cancer-associated single nucleotide polymorphisms and examined the PRS as a risk factor for breast cancer among women treated with SERMs. The PRS ranged from 3.98 to 7.74, with a one-unit change associated with a 42 % increase in breast cancer (OR = 1.42; P = 0.0002). The PRS had a stronger association with breast cancer among high-risk women with no first-degree family history (OR = 1.62) compared to those with a positive family history (OR = 1.32) (Pintx = 0.04). There was also suggestion that PRS was a stronger risk factor for ER-positive (OR = 1.59, P = 0.0002) than ER-negative (OR = 1.05, P = 0.84) breast cancer (Pintx = 0.10). Associations did not differ by tamoxifen or raloxifene treatment, age at trial entry, 5-year predicted Gail model risk or other clinical variables. The PRS is a strong risk factor for ER-positive breast cancer in moderate to high-risk individuals treated with either tamoxifen or raloxifene for cancer prevention. These data suggest that common genetic variation informs risk of breast cancer in women receiving SERMs.

KW - Mammographic density

KW - Polygenic risk score

KW - SERMs

KW - Single nucleotide polymorphisms (SNPs)

UR - http://www.scopus.com/inward/record.url?scp=84921924002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921924002&partnerID=8YFLogxK

U2 - 10.1007/s10549-014-3175-4

DO - 10.1007/s10549-014-3175-4

M3 - Article

C2 - 25575444

AN - SCOPUS:84921924002

VL - 149

SP - 517

EP - 523

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -